Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinjia Liangfu Granules (新加良附颗粒) is a Traditional Chinese Medicine (TCM) in granule form. The name "Xinjia" (新加) translates to "newly added" or "plus," suggesting that this formulation is a modified version of the traditional "Liangfu Pill" (良附丸). The traditional Liangfu Pill is composed of Gao Liang Jiang (Rhizoma Alpiniae Officinarum) and Xiang Fu (Rhizoma Cyperi), and is primarily used to warm the stomach, regulate qi, and relieve pain, particularly for conditions like stomach pain, acid reflux, and abdominal distension caused by cold stagnation and qi stagnation. However, specific details regarding the "newly added" components in Xinjia Liangfu Granules, its precise mechanism of action beyond the traditional Liangfu Pill, its developers, manufacturers, or specific clinical trial data are not publicly documented in available sources. Therefore, its exact composition and unique therapeutic profile remain largely unknown.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xinjia Liangfu Granules.